Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.46 |
| ▸ | S100B | P04271 | 1/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435805 | 0.88 | MAPT (0.46) | GAANPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL6414699 | 0.87 | MAPT (0.46) | DDX3XGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6413566 | 0.87 | BIRC5 (0.48) | DDX3XGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6418252 | 0.87 | RRM1 (0.49) | DDX3XGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6414918 | 0.84 | DDX3X (0.63) | DDX3XGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6432629 | 0.83 | KMT2A (0.56) | DDX3XGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6432172 | 0.83 | GAA (0.47) | GAANPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL6414142 | 0.82 | MAPT (0.43) | DDX3XGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6418326 | 0.80 | GAA (0.47) | GAANPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL6415963 | 0.80 | BIRC5 (0.52) | DDX3XGAANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | DDX3X 2134/4885S100B 4529/4885AMY1A 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.